2026-07-20 09:00
Biovica, a company specializing in blood-based cancer monitoring, today announced that it has received the first work order under its recently expanded Master Services Agreement with a current customer, one of the world’s leading pharmaceutical companies...
2026-07-16 12:30
Biovica, specializing in blood-based cancer monitoring, today announced that the Japanese Patent Office has issued a Notice of Allowance for a new patent application covering the use of TKa during ongoing treatment with immune checkpoint inhibitors in...
2026-07-14 09:00
Biovica, a company specializing in blood-based cancer monitoring, today announced that it has received a new work order from a current customer, one of the world’s leading pharmaceutical companies with a strong oncology pipeline. This marks the ninth...
2026-07-07 13:50
Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financial Officer (CFO). Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical...
2026-07-07 13:00
Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financial Officer (CFO). Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical...
2026-07-07 10:00
Biovica, a company specializing in blood-based cancer monitoring, today announces an expanded Master Services Agreement with a current customer, one of the world’s leading pharmaceutical companies, which has a broad and active oncology pipeline. Under...
2026-07-01 09:15
Biovica, specializing in blood-based cancer monitoring, today announced that the Japanese Patent Office has granted a new patent covering the use of TKa in relation to immune checkpoint inhibitor treatment in cancer patients.
2026-06-30 13:00
Biovica, specializing in blood-based cancer monitoring, today announces that it has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, Inc., announced in May 2025. Under the agreement, Tempus was intended to offer DiviTum®...
2026-06-30 12:40
Biovica, specializing in blood-based cancer monitoring, today announces that it has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, Inc., announced in May 2025. Under the agreement, Tempus was intended to offer DiviTum®...
2026-06-30 08:00
Annual Report for the financial year 2025/2026 for Biovica international AB is published today on our website.
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects